1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Nipro Corporation

Nipro Corporation

NPRRF
Nipro CorporationUS flagOther OTC
9.69
USD
-0.27
- -
1.58BMarket Cap
Nipro Corporation
NPRRF
(Other OTC)

Recent

price

9.69

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
1,544.74
1,631.99
1,413.23
1,912.07
2,110.32
2,161.07
2,142.3
2,377.96
2,588.58
2,713.21
2,793.18
3,033.73
3,342.81
3,597.79
3,953.49
4,050
1,846.09
Revenue per Share
19.35
35.29
59.99
18.19
80.95
116.22
67.57
71.14
73.68
-75.3
87.12
82.5
28.04
68.11
31.36
82.8
7.23
Basic EPS, GAAP
171.86
119.2
132.48
137.02
181.64
176.43
199.35
246.85
251.1
228.37
405.24
418.24
63.74
447.2
419.9
335.12
- -
Free Cash Flow per Basic Share
23.95
21.2
23.43
32.03
32.37
31.6
24.25
39
30.03
22.47
10.55
32.03
26.04
18.55
27.04
23.06
- -
Dividend per Share
593.59
1,022.13
816.12
870.77
930.13
928.11
969.72
1,010.17
1,063.09
975.89
1,052.89
1,097.91
1,103.14
1,157.1
1,160.31
1,221.33
1,143.48
Book Value per Share
752.66
729.72
554.09
595.98
872.73
769.72
789.56
826.88
803.96
783.79
884.43
1,024.28
1,276.36
1,438.72
1,693.52
1,735.56
1,597.29
Tangible Book Value per Share
127
130
171
157
154
170
168
166
165
163
163
163
163
163
163
163
163
Basic Weighted Avg Shares
195,942
212,013
241,020
300,752
325,084
366,650
359,699
395,397
426,399
442,516
455,559
494,789
545,199
586,785
644,586
660,538
300,920
Sales/Revenue/Turnover
8.79
7.46
4.72
4.09
5.1
6.6
8
6.85
5.59
5.97
6.06
4.83
3.25
3.81
4.13
5.7
2.94
Operating Margin (%)
22,987
24,232
24,043
29,978
33,504
33,833
34,035
35,996
38,624
41,825
42,626
46,164
48,743
58,872
65,648
63,737
- -
Depreciation Expense
2,455
4,585
10,231
2,861
12,470
19,718
11,346
11,829
12,136
-12,281
14,209
13,455
4,574
11,109
5,113
13,504
1,178
Net Income, GAAP
62.16
54.48
41.2
75.94
35.64
25.89
36.67
27.76
44.07
- -
14.16
35.18
64.63
36.68
65.05
46.58
0.28
Effective Tax Rate (%)
1.25
2.16
4.24
0.95
3.84
5.38
3.15
2.99
2.85
-2.78
3.12
2.72
0.84
1.89
0.79
2.04
0.39
Profit Margin (%)
40,620
61,346
74,216
45,405
71,945
115,970
134,983
177,903
168,676
143,626
149,867
125,466
186,379
157,691
223,873
166,295
168,077
Working Capital
179,635
190,294
228,993
224,346
229,340
271,407
314,265
383,061
390,546
370,610
397,384
402,210
448,730
440,281
468,247
406,230
445,945
LT Debt
109,037
113,950
128,762
135,958
178,808
175,505
176,405
183,484
171,829
161,235
174,051
199,866
242,173
269,787
311,620
334,771
298,142
Total Equity
1.77
1.7
1.42
0.57
1.9
3.01
2.91
2.87
1.86
- -
3.32
2.07
0.77
1.6
1
2.07
0.93
Return on Invested Capital (%)
0.92
1.36
2.43
0.67
2.7
4.04
2.19
2.07
1.99
- -
2.33
1.95
0.61
1.69
0.72
1.84
0.49
Return on Capital (%)
3.25
4.41
7.52
2.07
8.9
13.11
7.08
7.15
7.07
-7.35
8.59
7.67
2.55
6.03
2.71
6.95
0.63
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
195,406
- -
224,130
LT Borrowings
414,969
- -
420,045
LT Finance Leases
25,312
- -
25,900
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
163
- -
163
Market Capitalization
209,952
223,042
199,157

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
524,166
- -
564,656
Cash, Cash Equivalents & STI
99,667
- -
92,576
Accounts Receivable, Net
160,240
- -
173,037
Inventories
227,063
- -
249,803
Total Current Liabilities
366,475
- -
396,579
Payables & Accruals
- -
- -
- -
ST Debt
195,406
- -
224,130
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.03%
14.07%
7.43%
Free Cash Flow
59.65%
98.76%
-20.16%
Net Income, GAAP
-27.08%
36.34%
164.11%
Sales/Revenue/Turnover
6.13%
7.75%
2.47%
Total Cash Common Dividend
11.98%
37.46%
-14.68%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
140,594
145,271
153,270
147,650
586,785
2025
- -
- -
- -
- -
644,586
2026
- -
- -
- -
- -
660,538

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
25.13
- -
- -
- -
68.11
2025
- -
- -
- -
- -
31.36
2026
- -
- -
- -
- -
82.8

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
18.55
2025
- -
- -
- -
- -
27.04
2026
- -
- -
- -
- -
23.06
Similar Companies
Tetratherix Ltd. (TTX.AX)
Medius Holdings Co., Ltd. (3154.T)
Opsens Inc. (OPSSF)
Fisher & Paykel Healthcare Corporation Limited (FPH.NZ)
Hologic, Inc. (HOLX)
Gerresheimer AG (GRRMF)
Business
Nipro Corporation (NPRRF) manufactures and sells medical devices, pharmaceuticals, and pharmaceutical packaging products worldwide. Founded in 1954 and headquartered in Osaka, Japan, the company operates through four core business segments including renal care products such as dialysis machines, dialyzers, RO water treatment systems, and blood tubing sets; general hospital supplies encompassing syringes, IV catheters, infusion sets, lancets, and safety needles under brands like 4SURE; pharmaceutical packaging solutions featuring glass ampoules, vials, pre-fillable syringes, and cartridges; and diabetes care devices including pen needles, blood glucose monitors like 4SURE Smart, and home infusion therapy pumps such as Surefuser+. Nipro serves healthcare providers, pharmaceutical companies, and patients across Japan, Asia, North and South America, and Europe with manufacturing facilities and subsidiaries in key markets. In recent developments, Nipro Trading, a consolidated subsidiary, acquired 70% of Sichuan Pure Science and Technology Co., Ltd., a Chinese dialysis RO equipment manufacturer, in October 2024 to bolster its hemodialysis presence in China; entered a strategic distribution partnership with Haselmeier in April 2024 to exclusively promote the PiccoJect autoinjector in Japan; completed the acquisition of MTN Neubrandenburg GmbH in Germany in 2024 to strengthen renal care capabilities; and announced in October 2025 its intent to acquire shares in G2/Spryte Holdco, LLC, a U.S. affiliate, following FDA IDE approval for the nOCT imaging system trial in brain aneurysm treatment.